CDH1 and neoplasm: Based on the current knowledge regarding potential biomarkers of tumour aggressiveness, Aryl hydrocarbon receptor (AhR), N-cadherin, E-cadherin and CD147 were selected to be analysed in thyroid carcinomas for the following reasons.